---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-140873"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:30:24.217997+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quince raises $11.5M in private placement of stock and warrants; management participates

## Summary
- Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.
- Common warrants exercisable at $1.20/share for 5 years; pre-funded warrants exercisable at $0.001/share.
- Management investors: CEO Dirk Thye ($200k), COO Brendan Hannah ($50k), President Charles Ryan ($10k).
- Company to file resale registration statement within 120 days under Registration Rights Agreement.

## SEC filing metadata
- accession: 0001193125-25-140873
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/0001193125-25-140873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/d31831d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-140873
- JSON: https://secwatch.observer/filing/0001193125-25-140873.json
- Plain text: https://secwatch.observer/filing/0001193125-25-140873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.